Health Rounds: Weight gain from various antidepressants varies slightly
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here.
By Nancy Lapid
July 2 (Reuters) -Hello Health Rounds Readers! Antidepressants have long been associated with weight gain, but today we have a study that finds little difference among a wide variety of the drugs. We also cover a study that suggests shingles vaccines may be heart protective and a potential advance to improve testing for sleep disorders.
Health Rounds will be off for the July 4 U.S. holiday and back with important medical studies and advances next week.
Weight gain from antidepressants varies only slightly
Weight gain after starting treatment with antidepressants isn’t likely to vary much depending on the drug, according to a report published on Monday in Annals of Internal Medicine.
Among the eight antidepressants studied, bupropion (Wellbutrin) was consistently associated with the least weight gain, researchers said.
However, only small differences in weight changes were likely among patients taking any of the drugs, they said.
The researchers emulated a randomized trial to compare the drugs using health records of more than 183,000 adults who were starting treatment with either bupropion, sertraline (Zoloft), citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac), venlafaxine (Effexor), paroxetine (Paxil), or duloxetine (Cymbalta).
Zoloft - the most commonly prescribed first-line drug used by 20% of participants - was associated with an average gain of nearly 0.5 pounds (0.2 kilograms) after six months.
Users of Lexapro, Paxil and Cymbalta gained an average of 0.7 to 0.9 pounds (0.3 to 0.4 kilograms) more than those on Zoloft after 6 months, and were 10% to 15% more likely to have gained at least 5% of their baseline weight.
Wellbutrin users gained about half a pound less on average than Zoloft users, and they were 15% less likely to gain at least 5% of their baseline weight.
The effect of Prozac use on weight change was similar to that of Zoloft.
“Clinicians and patients could consider these differences when making decisions about specific antidepressants, especially given the complex relationships of obesity and depression with health, quality of life, and stigma,” the researchers said.
Shingles vaccine linked with cardiovascular benefits
Shingles vaccines may have the added benefit of protecting against strokes and heart attacks, a new study suggests.
Researchers compared 27,093 adults vaccinated against herpes zoster virus with five times as many similar people who had not been vaccinated. During five years of follow-up, rates of stroke were 1.6% among those who were vaccinated versus 2.2% for those who did not get the shingles shot. Rates of heart attack were 1.3% vs 1.8%, respectively.
The study was not a randomized trial and so cannot prove the vaccine actually prevented any cardiovascular events.
Everyone in the study had received the earliest shingles vaccine, Zostavax from Merck & Co MRK.N, which is no longer on the U.S. market.
Shingrix, the currently available vaccine from GSK GSK.L, is superior to the earlier shot at preventing shingles and recommended in the United States for all adults age 50 and older and for younger adults who are or will be at increased risk for shingles due to immunodeficiency or immunosuppression, the authors note in a report published in the American Journal of Preventive Medicine.
The benefits of the older Merck vaccine for lowering stroke and heart attack risks were greatest in people with diabetes, but patients with other conditions, including high blood pressure, chronic obstructive lung diseases, high cholesterol, or obesity, also had reductions in risk, the researchers found.
The researchers called for similar studies on the effect of Shingrix on heart attack and stroke, but added that these results may be relevant in parts of the world where Zostavax remains available.
Monitoring sleep with a single ECG lead
Artificial intelligence combined with just a single electrocardiography lead could eventually replace the multiple awkward wires on the head and chest currently used for diagnosing sleep disorders, researchers say.
“Our method achieves expert-level agreement with the gold-standard polysomnography without the need for expensive and cumbersome equipment and a clinician to score the test,” study leader Bhavin Sheth of the University of Houston said in a statement.
“This advancement... paves the way for more accessible, cost-effective sleep studies,” Sheth said.
The electrocardiography-based AI model was trained on data from 3,000 children and adults and then tested on data from an additional 1,000 participants, according to a report in Computers in Biology and Medicine.
Previously, sleep monitoring methods that did not include brain monitoring with electroencephalography had yielded “suboptimal” results, suggesting that EEG would always be necessary, the researchers said.
The new results challenge that notion, they added.
“Our findings establish that electrocardiography-based automated sleep staging” – or, cardiosomnography – “can achieve comparable performance to polysomnography,” they concluded.
Reporting by Nancy Lapid; Editing by Bill Berkrot
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
